Talphera Inc. (TLPH)

[Pandemonium75]

In a sea of red, which thankfully there are things such as Puts...this is still doing okay. I was okay with ER and outlook. Cheap shares for long hold. Added 15% to my long position today.

[Pandemonium75]

Solid. Holding so far.

[TFMG]

ACRX - Perfect Trend Bounce 0.168 Levels On Daily

AcelRx Pharmaceuticals , Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

SHORT INTEREST
15.09M 07/15/19

Average Recommendation: BUY

Average Target Price: 7.71

P/E Current
-3.02

P/E Ratio (with extraordinary items)
-3.90

[ClayTrader]

* * $ACRX Video Chart 07-29-2019 * *

Link to Video - click here to watch the technical chart video

[cervelo]

i agree

[NB888]

T

[ClayTrader]

* * $ACRX Video Chart 07-09-2019 * *

Link to Video - click here to watch the technical chart video

[north40000]

ACRX

"AcelRx added to the Russell 2000® and 3000® indexes

REDWOOD CITY, Calif., July 1, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Company has been added as a member of the Russell 2000® and Russell 3000® Indexes effective at the opening of trading today, July 1, 2019.

"We're pleased to be included in these widely followed indexes which raises our visibility with institutions and investors, and reflects the progress we have made as a commercial stage company," said Vince Angotti, Chief Executive Officer at AcelRx.

The annual reconstitution of the Russell indexes captures the 4,000 largest U.S. stocks as of May 10, ranking them by total market capitalization. Membership in the Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell's U.S. indexes. Russell indexes are part of FTSE Russell, a leading global index provider. For more information on the Russell 2000 and 3000 Indexes and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso®(sufentanil sublingual tablet system, SST system, 15 mcg), being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is an investigational drug and not approved in the U.S. For additional information about AcelRx, please visit www.acelrx.com."

[BottomBounce]

$ACRX Garbage Book Value

Book Value Per Share (mrq) -0.10

[ClayTrader]

* * $ACRX Video Chart 06-29-2019 * *

Link to Video - click here to watch the technical chart video

[BK2831]

Tried to buy 700 after mkt @ 2.10 but only bought 230 before close. It bumped so fast this morning I couldn't get bought in. Sold the 230 @ 2.415. Sigh

[LOL83001]

And we have a 15% pop today. Welcome to small pharma SP. Hope ya bot some in last few day to avg down. Awaiting Q2 numbers and comments.

[cervelo]

this thing has turned into a real pig. did management all go on vacation?. we get fda approval and it has been all down hill since
But then again we have only lost 50% value over the last 30 days

[Pandemonium75]

This has a lot of upside assuming the drug takes off in trauma centers and is widely used, or accepted in Europe. Speculation still, but yes this price is about what it's cash valuation is, maybe a little higher.

[LOL83001]

Where did ya'll go? I just found this company and I like the circumstances. Low cap, low price, newly approved drug good market with less than 90 days sales, some more drugs in FDA pipeline, plenty of cash for operations, ability to raise secure dough- $25M debt facility ( though pricey). Building a small position. Hope for a nice pop in July and a good run from there on news of marketing/sales inroads. E.g. a couple of military contracts , a few more hospitals and surgical center chains. If this were retail, we'd be saying they have this in 500-1000 "doors" by year end. Am I wrong?

[lakingsphan0427]

This is a no-brainer long term hold exactly what I am doing..

[Clemdane]

Thanks - that makes a lot of sense. I like this one for the long term. I hope it makes it.

[bwrbad]

like your answer
peple don't realise this as a life saver.

opioides are addictive when misused and in wrong hand, but this has no chance to be misused. this would be a post-surgery and under similar acute incidence med of choice for pain control

I am surprise to see PPS and market cap of this stock is so low.

[crawford2012]

I understand what you are saying, but you have to remember this was brought to market because of a special need. This is not another opioid pill. This is needed by the DOD, war injuries, seriously injured people coming to the hospital and they need the pain to stop NOW!!!!

This product will become a hit. It is very much needed our people are cry babies they cannot handle pain so this will do the job.

Hope this helps.
Lotsnof time you will see a heavy up and down and more down or i should say red only to serve one purpose, get you to sell at a loss before it goes up.

Check out this stock perfect example.
Did the same thing and moved up then the same at a highr level then again and moved up now.
PAYS

[Pandemonium75]

Yeah. I still think this has a lot of potential long term. End of year or another year at least.

[Clemdane]

Good point. So no way they can obtain it after they get out of hospital (unless they there's some kind of Nurse Jackie situation at that hospital lol.)

[Pandemonium75]

Good question and not one I have any expertise on answering. I do believe this is a different kind of situation since this drug is not issuable via prescription and only used in hospitals and trauma centers.

[Clemdane]

How much do you think the price is held down by all the States suing pharmaceutical companies over the opioid epidemic?

[Pandemonium75]

Probably will be this way until vote to increase AS passes and dilution hits - but growing a company like this, creating liquidity by increasing AS isn't necessarily a bad thing.

[lakingsphan0427]

Cheezus! can someone stopped the bleeding..

[Pandemonium75]

Probably smart. I sold off some of my posn to rebuy when it hits low $2 again.

[ravens723]

Waiting to buy after next offering

[Bobwins]

ACRX is still a binary bet that mgmt can get industry acceptance of Dsuvia. Obviously the market expected/hoped for a miracle amt of revs to show up in Q1 after 19 whole days for the company to sign up health insurance plans, hospitals and get doctors to prescribe a new drug.

We don't know if ACRX will succeed. That uncertainty led to a selloff today after ACRX showed a small amt of revs in Q1.

Investors have to review and decide for themselves if mgmt will succeed over the long run. The sellers today don't have any special abilities. They don't know if ACRX will succeed next month or next year. They could be right or lose out on a big winner.

It's too early to tell.

Investors have to review the available info and decide for themselves. What happens today or tomorrow with the stock price won't matter. What happens with the sales reps matters.

[ThatBobGuy]

True, but is the market down 9% like this stock is? Hopefully it will turn around in the near future. This stock and the market I mean.

[Clemdane]

Whole market is a dump right now

[ThatBobGuy]

So is this a dip or a dump?

[Pandemonium75]

I doubt their intentions are to string anyone along. They want to make money like the rest of us and this kind of process takes a long time. I'll be buying into any dips. Long here several years.

[Lenard]

more stringing the shareholder along

[ravens723]

https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-reports-first-quarter-2019-financial-results-300846162.html

[Pandemonium75]

I am looking forward to the expanded pilot numbers and where we are on the DoD orders.

[lakingsphan0427]

Said the one who wants cheapies..You're funny

[ClayTrader]

* * $ACRX Video Chart 05-03-2019 * *

Link to Video - click here to watch the technical chart video

[ELMONOINVEST]

This is a real scammer company keep dropping f..k crazy

[Sangster17]

Already at $4.05 this morning. More interesting this week is going to be.

[lakingsphan0427]

Next week for sure and on to $5 after earnings..

[ravens723]

We break $4 today

[lakingsphan0427]

Inching in at $4 hopefully next week will be in the low $4 then $5 after earnings.. Lets hope that earnings will move the needle

[Bobwins]

Q1 earnings coming 5/8. The update on progress there will be crucial to near term stock performance. The formulary wins have been significant, with most major health insurance plans including Dsuvia but hospitals will be where the actual units will be ordered and used. Not sure how long it takes for hospitals to start ordering and using the drug. Looking forward to update at the Q1 earnings conference call.

[lakingsphan0427]

I think base on the past days of the trading sessions someone is accumulating big..It could be another insider buying or an institutional buying with deep pocket.. Either way it will get us up up and away..

GO ACRX!

[lakingsphan0427]

Yup it's always good when we see insiders are buying especially on the open market.. Guessing ACRX will be in the $4 range before their next earnings..

[Clemdane]

I'm almost back to the green. I was going to average down, but I got lazy. What I like though is the consistent insider buying on the open market. A Director bought another 19,000 shares in March.

[usmcallen]

It will probably Slam back down like it has a few times in the past. Need solid news for this to hold.

[lakingsphan0427]

Up 5.98% better yet I am now seeing green in my ACRX investment..

[Pandemonium75]

Almost tempted to add a little here. Pre-market two days in a row was 3.60-3.70, it wants to go up. It needs to go up.

[Pandemonium75]

I don't know either, but I think the people who bought low and planned on taking profits probably already did and now we had some consolidation, then some new money loading.